5.20
price down icon13.76%   -0.83
after-market 시간 외 거래: 5.03 -0.17 -3.27%
loading
전일 마감가:
$6.03
열려 있는:
$4.75
하루 거래량:
5.68M
Relative Volume:
4.22
시가총액:
$15.54M
수익:
-
순이익/손실:
$-16.60M
주가수익비율:
-5.8427
EPS:
-0.89
순현금흐름:
$-23.48M
1주 성능:
+21.21%
1개월 성능:
+27.14%
6개월 성능:
-60.02%
1년 성능:
-84.52%
1일 변동 폭
Value
$4.60
$5.38
1주일 범위
Value
$3.99
$9.82
52주 변동 폭
Value
$3.09
$36.60

Briacell Therapeutics Corp Stock (BCTX) Company Profile

Name
명칭
Briacell Therapeutics Corp
Name
전화
(604) 921-1810
Name
주소
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Name
직원
12
Name
트위터
Name
다음 수익 날짜
2024-10-28
Name
최신 SEC 제출 서류
Name
BCTX's Discussions on Twitter

BCTX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
BCTX
Briacell Therapeutics Corp
5.20 15.54M 0 -16.60M -23.48M -0.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2022-02-14 개시 H.C. Wainwright Buy

Briacell Therapeutics Corp 주식(BCTX)의 최신 뉴스

pulisher
03:38 AM

(BCT) Trading Performance and Risk Management (BCT:CA) - news.stocktradersdaily.com

03:38 AM
pulisher
Apr 26, 2025

BriaCell (BCTX) Prices Public Offering of Units to Raise $13.8 M - GuruFocus

Apr 26, 2025
pulisher
Apr 26, 2025

Increased Share Offering for XYZ Corp (XYZ) Priced Below Market - GuruFocus

Apr 26, 2025
pulisher
Apr 26, 2025

BriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail's Busy Cheering Clinical Milestone - MSN

Apr 26, 2025
pulisher
Apr 25, 2025

BriaCell Therapeutics (BCTX) Prices $13.8 Million Public Offerin - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

BriaCell's Stock Dips Following Public Offering Announcement - Finimize

Apr 25, 2025
pulisher
Apr 25, 2025

BriaCell Therapeutics Down 17% In US Premarket As Prices US$13.8 Million Public Offering - marketscreener.com

Apr 25, 2025
pulisher
Apr 25, 2025

BriaCell Therapeutics announces pricing of $13.8 million public offering - MSN

Apr 25, 2025
pulisher
Apr 24, 2025

(BCT) Trading Report (BCT:CA) - news.stocktradersdaily.com

Apr 24, 2025
pulisher
Apr 24, 2025

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering | BCTX Stock News - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

BriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail’s Busy Cheering Clinical Milestone - Investing.com India

Apr 24, 2025
pulisher
Apr 24, 2025

BriaCell Therapeutics Announces $13.8 Million Public Offering - TipRanks

Apr 24, 2025
pulisher
Apr 24, 2025

BriaCell Raises $13.8M: Strong Institutional Demand Drives Full Exercise of Underwriter Option - Stock Titan

Apr 24, 2025
pulisher
Apr 24, 2025

Briacell Therapeutics Says Units Priced At $4.50 Each For Gross Proceeds Of $13.8 Million - marketscreener.com

Apr 24, 2025
pulisher
Apr 24, 2025

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering - GlobeNewswire

Apr 24, 2025
pulisher
Apr 24, 2025

BriaCell reports complete lung metastasis resolution in breast cancer study By Investing.com - Investing.com South Africa

Apr 24, 2025
pulisher
Apr 24, 2025

BriaCell's Bria-OTS shows sustained success against breast cancer | 2025-04-24 | Investing News - Stockhouse

Apr 24, 2025
pulisher
Apr 24, 2025

BriaCell confirms 100% resolution of lung metastasis with Bria-OTS - TipRanks

Apr 24, 2025
pulisher
Apr 24, 2025

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher - Benzinga

Apr 24, 2025
pulisher
Apr 24, 2025

BriaCell (BCTX) Showcases Key Breast Cancer Trial Data at ASCO 2025 - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

BriaCell Jumps 41% in U.S. Pre-market Trading, Reports Complete Lung Metastasis Resolution in Patient - marketscreener.com

Apr 24, 2025
pulisher
Apr 24, 2025

BriaCell (BCTX) Reports Positive Outcomes in Bria-OTS Cancer Study | BCTX Stock News - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

BriaCell’s Bria-OTS Shows Promising Results in Metastatic Breast Cancer Study - TipRanks

Apr 24, 2025
pulisher
Apr 24, 2025

BriaCell Therapeutics stock soars on lung metastasis treatment success By Investing.com - Investing.com Nigeria

Apr 24, 2025
pulisher
Apr 24, 2025

BriaCell reports complete lung metastasis resolution in breast cancer study - Investing.com India

Apr 24, 2025
pulisher
Apr 24, 2025

BriaCell Therapeutics stock soars on lung metastasis treatment success - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™ | BCTX Stock News - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™ - GlobeNewswire

Apr 24, 2025
pulisher
Apr 24, 2025

Breakthrough: BriaCell's Novel Cancer Treatment Eliminates Lung Metastasis in Advanced Breast Cancer Patient - Stock Titan

Apr 24, 2025
pulisher
Apr 23, 2025

H.C. Wainwright maintains $32 target on BriaCell stock - Investing.com Australia

Apr 23, 2025
pulisher
Apr 23, 2025

H.C. Wainwright maintains $32 target on BriaCell stock By Investing.com - Investing.com South Africa

Apr 23, 2025
pulisher
Apr 23, 2025

BriaCell Therapeutics Corp. - Baystreet.ca

Apr 23, 2025
pulisher
Apr 23, 2025

Stocks In Play: BriaCell Therapeutics Corp. - Barchart.com

Apr 23, 2025
pulisher
Apr 23, 2025

BriaCell to Present Key Clinical Data at ASCO 2025 - TipRanks

Apr 23, 2025
pulisher
Apr 23, 2025

BriaCell Announces Four Clinical Data Presentations at ASCO 2025 | BCTX Stock News - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

BriaCell Announces Four Clinical Data Presentations at ASCO 2025 - GlobeNewswire

Apr 23, 2025
pulisher
Apr 23, 2025

Major Phase III Breast Cancer Treatment Update: BriaCell Unveils 4 Clinical Studies at ASCO 2025 - Stock Titan

Apr 23, 2025
pulisher
Apr 22, 2025

Briacell Therapeutics Files For Offering Of Up To 2.3 Mln Common Units, Up To 2.3 Mln Pre-Funded Units - marketscreener.com

Apr 22, 2025
pulisher
Apr 22, 2025

Innovative Company Announces New Common Unit Offering | BCTX Stock News - GuruFocus

Apr 22, 2025
pulisher
Apr 22, 2025

BriaCell Therapeutics: Promising Phase 3 Trial Progress and Strategic Financial Management Justify Buy Rating - TipRanks

Apr 22, 2025
pulisher
Apr 22, 2025

BriaCell Enrollment Accelerates In Phase 3 Study For Advanced Metastatic Breast Cancer - Nasdaq

Apr 22, 2025
pulisher
Apr 22, 2025

BriaCell Advances Phase 3 Study in Metastatic Breast Cancer - TipRanks

Apr 22, 2025
pulisher
Apr 22, 2025

BriaCell (BCTX) Advances Phase 3 Trial for Bria-IMT in Metastatic Breast Cancer | BCTX Stock News - GuruFocus

Apr 22, 2025
pulisher
Apr 22, 2025

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC) - GlobeNewswire

Apr 22, 2025
pulisher
Apr 22, 2025

Fast-Tracked Phase 3 Breast Cancer Treatment Shows Major Enrollment Surge: 75 Patients Join Critical Trial - Stock Titan

Apr 22, 2025
pulisher
Apr 22, 2025

(BCT) Daily Stock Insights (BCT:CA) - news.stocktradersdaily.com

Apr 22, 2025

Briacell Therapeutics Corp (BCTX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
자본화:     |  볼륨(24시간):